

Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer's disease

Gemma Salvadó^{1,#}, Kanta Horie^{2,3,4}, Nicolas R. Barthélemy^{2,3}, Jacob W. Vogel^{1,5}, Alexa Pichet Binette¹, Charles D. Chen⁶, Andrew J Aschenbrenner^{3,7}, Brian A. Gordon⁶, Tammie L.S. Benzinger^{6,7}, David M. Holtzman^{3,7}, John C. Morris^{3,7}, Sebastian Palmqvist¹, Erik Stomrud^{1,8}, Shorena Janelidze¹, Rik Ossenkoppele^{1,9,10}, Suzanne E. Schindler^{3,7}, Randall J. Bateman^{2,3,7}, Oskar Hansson^{1,8,#}

¹ Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden

² The Tracy Family SILQ Center, Washington University School of Medicine, St Louis, MO, United States

³ Department of Neurology, Washington University School of Medicine, St. Louis, MO, United States

⁴ Eisai Inc., Nutley, NJ, United States

⁵ Department of Clinical Science, Malmö, SciLifeLab, Lund University, Lund, Sweden

⁶ Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA

⁷ Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA

⁸ Memory Clinic, Skåne University Hospital, Malmö, Sweden

⁹ Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands

¹⁰ Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands

Corresponding authors:

Oskar Hansson, MD, PhD

Memory Clinic, Skåne University Hospital

SE-205 02, Malmö, Sweden

E-mail: oskar.hansson@med.lu.se; Tel: +46 (0)40 331000

Or

Gemma Salvadó, PhD

Clinical Memory Research Unit, Department of Clinical Sciences

SE-205 02, Malmö, Sweden

E-mail: gemma.salvado@med.lu.se; Tel: +46 (0)40 331000

39 Abstract

40 Biological staging of individuals with Alzheimer's disease (AD) may improve diagnostic
 41 and prognostic work-up of dementia in clinical practice and the design of clinical trials.
 42 Here, we created a staging model using the Subtype and Stage Inference (SuStaln)
 43 algorithm by evaluating cerebrospinal fluid (CSF) amyloid- β ($A\beta$) and tau biomarkers in
 44 426 participants from BioFINDER-2, that represent the entire spectrum of AD. The
 45 model composition and main analyses were replicated in 222 participants from the
 46 Knight ADRC cohort. SuStaln revealed in the two cohorts that the data was best
 47 explained by a single biomarker sequence (one subtype), and that five CSF biomarkers
 48 (ordered: $A\beta_{42/40}$, tau phosphorylation occupancies at the residues 217 and 205
 49 [pT217/T217 and pT205/T205], microtubule-binding region of tau containing the
 50 residue 243 [MTBR-tau243], and total tau) were sufficient to create an accurate
 51 disease staging model. Increasing CSF stages (0-5) were associated with increased
 52 abnormality in other AD-related biomarkers, such as $A\beta$ - and tau-PET, and aligned with
 53 different phases of longitudinal biomarker changes consistent with current models of
 54 AD progression. Higher CSF stages at baseline were associated with higher hazard
 55 ratio of clinical decline. Our findings indicate that a common pathophysiologic
 56 molecular pathway develops across all AD patients, and that a single CSF collection is
 57 sufficient to reliably indicate the presence of both AD pathologies and the degree and
 58 stage of disease progression.

59 Introduction

60 Currently, more than 50 million people are affected by dementia and this number is
 61 expected to more than double by 2050¹. Alzheimer's disease (AD) is the most common
 62 form of dementia, characterized by the accumulation of extracellular plaques containing
 63 amyloid- β (A β) and intracellular tau aggregates in the forms of tau tangles and neuropil
 64 threads². Over the last two decades, the AD field has moved towards the use of
 65 biomarkers to support the diagnostic and prognostic work-up, rather than relying solely
 66 on clinical symptoms³. This has been made possible by advancements of imaging and
 67 fluid biomarkers that accurately track AD pathology *in vivo*. Given that the accumulation
 68 of pathology can take many years to decades³, before any clinical symptoms appear,
 69 the use of biomarkers is critical to ensuring an early and reliable detection of AD⁴. Key
 70 biomarkers may help to improve patient diagnosis, management and prognosis⁵⁻⁸. And
 71 the use of AD biomarkers will be even more important when disease-modifying
 72 treatments become widely available⁹⁻¹¹. In this context, a more sophisticated
 73 personalized medicine approach of AD, based on high performing AD biomarkers, will
 74 become crucial to select the most optimal participants for specific treatments and for
 75 enrolment in new clinical trials.

76 In recent years, multiple cerebrospinal fluid (CSF) biomarkers targeting different
 77 pathophysiological mechanisms have been developed (see ⁴ for a review). There has
 78 been an increasing interest in developing biomarkers for measuring tau species
 79 phosphorylated at different residues. Among the phosphorylated tau (p-tau) species, p-
 80 tau181¹²⁻¹⁷, p-tau217^{12,13,15,18,19}, and p-tau231^{15,20-22} or the phosphorylation
 81 occupancies have been studied in depth, and have shown strong associations with A β
 82 pathology and moderate associations with tau (as measured by both PET^{18,23} and
 83 neuropathology^{24,25}). These biomarkers have shown their utility on improving the
 84 diagnostic work-up of AD and the prediction of disease progression^{12,13,19,26,27}. Other
 85 biomarkers, such as p-tau205 or the occupancy (pT205/T205)²⁸⁻³⁰ and microtubule
 86 binding region (MTBR) of tau containing the 243 residue (MTBR-tau243)^{31,32}, have
 87 been more closely related to tau tangle pathology. Importantly, some of these CSF
 88 biomarkers were shown to become abnormal at different phases during the
 89 progression of autosomal dominant AD (ADAD)²⁹, suggesting a sequence of CSF
 90 biomarker changes that may serve as a measurable biological indicator tracking
 91 advancing disease progression.

92 The progression of A β - or tau- pathology across the brain has been previously used to
 93 stage participants across the AD *continuum*³³⁻³⁸. However, these models need at least
 94 one A β - or tau-PET scan, which is expensive, and requires specialized personnel and

95 facilities. Further, information of only one pathological measure (e.g., A β or tau) can be
 96 obtained from these images. On the other hand, CSF biomarkers are less expensive,
 97 more accessible, and multiple pathological measures may be obtained from a single
 98 sample. Given this, and with the idea that different CSF biomarkers may become
 99 abnormal at different stages of the disease, we aimed to generate a data-driven
 100 staging scheme for sporadic AD using key CSF tau biomarkers in combination with
 101 CSF A β 42/40. An unresolved question is whether there is a single molecular pathway
 102 throughout the AD *continuum*, or whether there are subtypes of AD following different
 103 fluid biomarker trajectories, as has been shown for regional spread of insoluble tau
 104 tangles^{36,39,40}.

105 To test this, we used Subtype and Stage Inference (SuStaln)⁴¹ to model the most likely
 106 sequence of CSF biomarker abnormalities that occur along the AD time course. This
 107 machine-learning method uses cross-sectional data to order biomarker abnormalities in
 108 a probabilistic manner and at the same time addresses possible diverging trajectories
 109 of this ordering. With this approach, we staged 426 participants of the Swedish
 110 BioFINDER-2 study, ranging from cognitively unimpaired (CU) participants to patients
 111 with mild cognitive impairment (MCI) or dementia. This model was used to assign each
 112 participant to a fluid biomarker stage, which was subsequently correlated with
 113 established AD key features such as A β - and tau-PET, cortical thickness, and
 114 cognition. Next, we investigated the accuracy of our staging model to predict amyloid
 115 (A) and tau (T) status as defined by PET⁴², as well as its potential as a diagnostic tool
 116 for distinguishing diagnostic groups. Using longitudinal data, we further determined
 117 trajectories of several key AD-biomarkers based on participants baseline fluid
 118 biomarker disease stage. We also tested the clinical utility of our novel staging system
 119 for predicting clinical progression. Finally, we performed the main analyses in the
 120 independent cohort (the Charles F. and Joanne Knight Alzheimer Disease Research
 121 Center [Knight-ADRC]), which included 222 participants. Altogether our results suggest
 122 that participants in the AD *continuum* progress along a single path and can be
 123 biologically staged using a single sample of CSF. This may have important implications
 124 in the clinical practice and in the selection of participants for future clinical trials.

125

126 Results

127 A total of 426 participants of the Swedish BioFINDER-2 study (NCT03174938)¹⁹ with
 128 complete CSF data were included in this study. From these, 80 were cognitively
 129 unimpaired A β negative (CU-) and 79 cognitively unimpaired A β positive (CU+)
 130 participants, 88 were diagnosed with MCI and A β positive, 100 were diagnosed with

AD dementia and A β positive (ADD+), and 79 were assessed as non-AD patients (22 were A β positive). Demographic information is presented in Table 1. Of these, 220 participants had longitudinal CSF data available (Supplementary Table 1).

CSF staging model

We initially applied SuStaln to the BioFINDER-2 cohort using the following CSF biomarkers: the A β 42/40 ratio, the phosphorylated to non-phosphorylated tau ratio of pT205/T205, pT181/T181, pT217/T217, and pT231/T231, as well as the concentrations of MTBR-tau243 and total tau [the residue 151-153]) based on availability and previous literature. Through a process of model optimization (Ext. Data Fig. 1, see Methods for further details), we arrived on a model that excluded pT181/T181 and pT231/T231 due to information redundancy. SuStaln revealed that a single biomarker sequence best described the progressive abnormality of the selected biomarkers (Ext Data Fig. 1C). The final ordering of the model was the A β 42/40 ratio, pT217/T217, pT205/T205, MTBR-tau243 and total-tau (Fig. 1A), resulting in a five-stage model (plus stage 0 as a negative biomarker stage). All BioFINDER-2 participants were then classified into one of these biomarker-based disease stages based on their CSF levels, with 124 (29.1%) being at CSF stage 0, 35 (8.2%) at CSF stage 1, 53 (12.4%) at CSF stage 2, 49 (11.5%) at CSF stage 3, 87 (20.4%) at CSF stage 4 and 78 (18.3%) at CSF stage 5. Demographic, genetic, and diagnostic characteristics of these participants is shown in Ext Data Fig. 2. In brief, the CSF biomarker-based was not associated with sex ($\chi^2(5)=7.7$, $p=0.180$) or years of education ($\chi^2(5)=4.7$, $p=0.452$), but higher CSF stage was associated with older age ($\chi^2(5)=16.9$, $p=0.005$), carriership of an *APOE- $\epsilon 4$* allele ($\chi^2(5)=72.8$, $p<0.001$) and a more advanced clinical disease stage ($\chi^2(5)=478.6$, $p<0.001$, Ext Data Fig. 2A-E).

We then examined the distribution of the CSF biomarkers included in the model by CSF biomarker stage. Individual plots by CSF biomarker can be found in Fig. 1B and statistics for each biomarker and their differences by CSF stage can be found in Supplementary Table 2. In summary, degree of abnormality of all biomarkers increased with higher CSF stages, although their trajectories were different. CSF A β 42/40 and pT205/T205 had a steep increase at stage 1 and stage 3, respectively, and then continued increasing but in a lower degree. On the other hand, pT217/T217 (CSF stage 2) and MTBR-tau243 (CSF stage 4) levels continued to increase at all subsequent CSF stages in a similar degree after crossing the threshold for positivity. Also, both pT217/T217 and MTBR-tau243 reached very high levels compared to the reference control group (z-score>10). These different biomarker trajectories revealed

that the included CSF biomarkers exhibit different behaviours across the disease continuum, aside from the biomarker disease stage at which they become abnormal. This is summarized in figure 1C, in which the smoothed locally estimated scatterplot smoothing (LOESS) regression of all CSF biomarkers are plotted.

Finally, we assessed the stability of our model using the longitudinal CSF data over a mean (SD) of 2.1 (0.2) years (n=220, Supplementary Table 1). We observed that most participants remained at the same stage (N=183, 83.2%) or progressed (n=29, 13.2%), while only few regressed (n=8, 2.9%, Ext Fig. 3A-B). Of those that progressed, most (n=25, 86.2%) progressed only one CSF stage during the two-year follow-up. This indicates a high stability of our model over time.

CSF biomarker stages are associated with AD pathology, biomarkers and cognition

Next, we investigated the association between CSF stages and insoluble A β aggregates (A β -PET), insoluble tau aggregates (tau-PET), neurodegeneration (cortical thickness and CSF neurofilament light [NfL]) and cognition, using a global cognitive composite sensitive to early AD changes (modified version of preclinical Alzheimer's Cognitive Composite [mPACC])³⁵, Fig. 2). The degree of biomarker abnormality increased with higher CSF stages, although the trajectories were different. For instance, A β -PET was the first to start increasing (already at CSF stage 1 [A β 42/40 stage], Δ z-score=1.12, p=0.032 compared to the previous stage) and continued to increase until the CSF stage 5 (total-tau stage), where it reached a plateau. However, it was at CSF stage 2 (pT217/T217) that the mean of A β -PET was above 1.96SD (95%CI) of CU- levels (mean[SD] z-score=4.01[2.71]). Tau-PET was the next biomarker to show a significant increase, emerging at CSF stage 3 (pT205/T205 stage, Δ z-score=2.09, p<0.001), in which its mean was already above 1.96SD of CU- (mean[SD] z-score=2.02[3.16]). Notably, tau-PET levels continued to significantly increase in all subsequent CSF stages. The mPACC followed a similar trajectory, starting to increase also at CSF stage 3 (pT205/T205 stage, Δ z-score=0.92, p=0.004), and crossing the 1.96SD threshold at the following stage (mean[SD] z-score=2.60[1.84]). Finally, both measures of neurodegeneration (cortical thickness and CSF NfL) showed a significantly lower degree of abnormality compared to the other biomarkers, even in the most advanced CSF stages. The abnormality of cortical thickness significantly increased at CSF stage 3 (pT205/T205 stage, Δ z-score=0.80, p=0.006), but it was above the 1.96SD (95%CI) threshold only at the last CSF stage (total-tau stage, mean[SD] z-score=2.07[1.91]). CSF NfL, on the other hand, only

showed significant differences between CSF stages 3 and 4 (Δz -score=0.36, $p=0.016$), but did not cross the 1.96SD threshold at any CSF stage. Statistics of each these AD biomarkers and their differences per CSF stage can be found in Supplementary Table 3.

We further studied the associations between our CSF-based staging model and other biomarkers as additional analyses. For tau-PET, we quantified the signal in different brain regions, using the previously validated ROIs reflecting the different Braak stages⁴³. Early (Braak I) and intermediate (Braak III-IV) regions of tau deposition become abnormal at CSF stage 3 (pT205/T205 stage, Braak I: mean z-score: 2.26; Braak III-IV: mean z-score: 1.97) and later regions (Braak V-VI) become abnormal at the CSF stage 4 (MTBR-tau243 stage, mean z-score: 4.58; Ext Data. Fig. 4 and Supplementary Table 4). Noteworthy, the number of participants with Braak I z-scores over 1.96SD at CSF stage 3 was higher than that with Braak III-IV ($n=21$, 42.9% vs. $n=14$, 28.6%).

We also examined different measures of cognitive function including composites for memory, executive, language and visuospatial functions, respectively. The first composite to cross the 1.96SD threshold was memory at CSF stage 4 (mean z-score: 2.18), and kept increasing in the next CSF stage (Ext. Data Fig. 5 and Supplementary Table 5). This was followed by the executive function composite, which was above the threshold at CSF stage 5 (t-tau stage, mean z-score: 2.15). Finally, the language and visuospatial cognitive composites showed an increasing degree of abnormality across CSF stages but did not cross the 1.96SD threshold at any CSF stage.

CSF biomarker stages can be used for predicting A/T status and cognitive stages

Subsequently, we looked at the accuracy of our CSF staging model for predicting A β (A) and tau (T) status, as defined by PET³⁴. We first looked at each independent pathology dichotomously (*i.e.*, positive or negative) and independently and, later, we looked at the ordinal categories merging both pathologies (*i.e.*, A-T-, A+T-, and A+T+). The number of positive participants by CSF stage and category are presented in Fig. 3A. Using receiver operating characteristic (ROC) curves analyses, we determined that CSF stage 2 (pT217/T217 stage) was the optimal threshold for predicting A β -PET positivity with high accuracy (area under the curve and 95% confidence interval [AUC[95%CI]]=0.96[0.93, 0.98], sensitivity=0.93 and specificity=0.89, first column Fig. 3B and Supplementary Table 6). Tau-PET positivity was also predicted with high accuracy when using CSF stage 4 (MTBR-tau243 stage) as a threshold (AUC[95%CI]=0.95[0.93, 0.97], sensitivity=0.91 and specificity=0.92, second column Fig. 3B and Supplementary Table 6).

Ordinal logistic regression was used to assess the utility of CSF stages for predicting A/T status (*i.e.*, A-T-, A+T- or A+T+), and we calculated the c-index (an overall measure of discrimination equivalent to AUC for dichotomic outcomes) as a measure of accuracy. We observed that higher CSF stages were associated with higher predicted probabilities of being at more advanced A/T status (c-index[95%CI]=0.95[0.93, 0.97], last column Fig. 3B, and Supplementary Table 6). More specifically, participants at CSF stages 0 and 1 (negative biomarkers and A β 42/40 stages) had the highest probability of being A-T-, at CSF stages 2 and 3 (pT217/T217 and pT205/T205 stages) being A+T- and at CSF stages 4 and 5 (MTBR-tau243 and total-tau stages) of being A+T+. Only one participant was classified as A-T+, which was excluded from this analysis.

Finally, we also aimed at investigating whether our staging model could be used as a diagnostic tool. In the first analysis, we used the CSF staging model for predicting cognitive stages within the AD continuum (*i.e.*, excluding non-AD). Higher CSF stages were associated with more advanced cognitive stages (c-index[95%CI]=0.88[0.86, 0.91], first column Fig. 3C and Supplementary Table 6). The model predicted that participants at CSF stage 0 (negative biomarkers stage) had the highest probability of being CU-; at CSF stages 1 and 2 (A β 42/40 and pT217/T217 stages) were more probably CU+ (as assessed by CSF), at CSF stage 3 (pT205/T205) MCI+ and, finally, at CSF stages 4 and 5 (MTBR-tau243 and total-tau) ADD+. Lastly, we aimed at differentiating cognitive impairment due to AD or due to other neurodegenerative diseases. We therefore compared patients with AD to patients with non-AD dementia, only including those with objective cognitive impairment (*i.e.*, MCI and dementia patients). Participants at CSF stage 2 (pT217/T217 stage) or higher with objective cognitive impairment had a high probability of having AD as the cause of their cognitive impairment (AUC[95%CI]=0.95[0.93, 0.98], sensitivity=0.97 and specificity=0.75, last column Fig. 3C-D and Supplementary Table 6).

267

268 **Longitudinal rates of change of AD biomarkers differ by CSF stages**

Next, we used longitudinal imaging and cognitive data to assess how AD biomarkers change over time based on the baseline CSF stage classification (Supplementary Table 7). The rate of accumulation of A β aggregates as measured with PET (n=218) increased at early CSF stages reaching the highest values at CSF stage 2 (pT217/T217 stage) and thereafter the rate decreased but still remained positive (Fig. 4 and Supplementary Table 8). On the other hand, the tau-PET (n=312), cortical thickness (n=300) and mPACC (n=342) exhibited monotonic increases in rates of change over time, with the rates starting to be significantly different from contiguous

277 CSF stages at CSF stage 3 (pT205/T205 stage; Fig. 4). Figure 4B depicts that tau-
278 PET, followed by mPACC had the highest rate of change (z-scored), while A β -PET and
279 cortical thickness had lower rates of change that were in a similar range.

280

281 **CSF biomarker stages predict clinical progression**

282 In the next set of analyses, we tested whether our CSF staging model was useful for
283 predicting subsequent clinical progression (up to 5-years of follow-up after the baseline
284 visit). First, we tested the ability of our model to predict progression to AD dementia
285 from CU or MCI status at baseline (progressors: n=41). Based on Kaplan-Meier
286 analyses (Fig. 5A), participants at higher CSF stages (4-5; MTBR-tau243 and total-tau
287 stages) at baseline had higher probability to progress to AD dementia, than those at
288 positive lower CSF stages (*i.e.*, 1-3). When adjusting for age, sex, and clinical status at
289 baseline (*i.e.*, CU or MCI), the hazard ratio (HR) was 5.2 (95%CI: [2.2, 12.6], $p < 0.001$)
290 when comparing participants at CSF stages 4 or 5 to participants at lower, but positive,
291 CSF stages (1-3, A β 42/40 to pT205/T205, reference; Fig. 5B and Supplementary Table
292 9). When including only those with MCI at baseline (progressors: 38/88), we still found
293 that those at CSF stages 4 or 5 at baseline had a significantly higher probability to
294 progress to AD dementia (HR[95%CI]=4.5[1.8, 10.8], $p < 0.001$, Fig. 5C-D and
295 Supplementary Table 9). Finally, we investigated the utility of the CSF staging model
296 when predicting progression from CU to MCI status (progressors: 11/159). Again, those
297 CU participants at higher CSF stages (4-5) at baseline, were much more prone to
298 progress to MCI with a HR of 16.0 (95%CI: 3.2, 81.1, $p < 0.001$, Fig. 5E-F and
299 Supplementary Table 9) compared to those in stage 1-3, supporting the clinical utility of
300 the proposed staging model. There were no progressors from CSF stage 0 in any case,
301 which prevented us from comparing these participants with the other CSF stages
302 groups. Kaplan-Meier curves for each individual CSF stage are depicted in Ext Data
303 Fig. 6.

304

305 **Replication in an independent cohort**

306 Finally, we replicated the staging model and the main analyses in the Charles F. and
307 Joanne Knight Alzheimer's Disease Research Center (Knight-ADRC) cohort (n=222,
308 Table 2). SuStaln selected one unique subtype as the optimal model with the same
309 CSF abnormality ordering as the one previously obtained in BioFINDER-2 (Fig. 6A). In
310 this cohort, however, there was slightly higher uncertainty between the ordering of first
311 two (A β 42/40 and pT217/T217) and the last two (MTBR-tau243 and total-tau) stages.
312 These differences may be mostly due to the difference in sample size, especially in
313 more advanced AD cases (only 9 mild AD dementia cases). Nonetheless, the overall

behaviour of these CSF biomarkers by the biomarker stages was similar to that in the main cohort (Fig. 6B and Supplementary Table 2). Further, the other AD biomarkers available (not included in the CSF staging model), showed similar trajectories to those in the discovery (BioFINDER-2) sample. A β -PET was once again the first modality to cross the 1.96SD threshold at CSF stage 1 (A β 42/Ab40 stage), followed by tau-PET in CSF stage 3 (pT205/T205 stage) and, finally, CSF NfL crossing this threshold at the final stage (total-tau stage; Fig. 6C and Supplementary Table 3). Neither the global cognitive composite nor AD cortical thickness signature crossed this threshold. The main difference compared with BioFINDER-2, was the lower degree of abnormality for all markers in the last CSF stages. This might be explained by the lower number of advanced patient cases in this cohort. The individual plots for each CSF and imaging biomarker by CSF stages are shown in Ext Data Fig. 7. Details of participants characteristics (Ext Data Fig. 2), tau-PET binding in different regions (Ext Data Figure 4 and Supplementary Table 4) and other cognitive measures (Ext Data Figure 5 and Supplementary Table 5) per CSF stage can be found in the Ext Data. Stability analyses, within participants with available longitudinal CSF measures (n=51, Supplementary Table 10), also showed that most participants remained at the same stage (n=46, 90.2%) or progressed (n=4, 7.8%) at follow-up (Ext Data Fig. 3C-D).

We also calculated the optimal CSF stages for predicting A β -PET and tau-PET positivity using ROC curves. As in the case of BioFINDER-2, CSF stage 2 (pT217/T217 stage) was optimal for predicting A β -PET positivity (AUC[95%CI]=0.89[0.85, 0.94], Fig. 6D&G and Supplementary Table 6), whereas CSF stage 4 (MTBR-tau243 stage) was optimal for predicting tau-PET positivity (AUC[95%CI]=0.94[0.91, 0.96], Fig. 6E&H). Consistent with findings in BioFINDER-2, higher CSF stages were predictive of more advanced A/T stages, as assessed by PET (c-index[95%CI]=0.89[0.86, 0.92], Fig. 6F&I, Supplementary Table 6). Being at CSF stages 0 and 1 (biomarker negative and A β 42/40 stage) was highly predictive of being A-T-, being at CSF stages 2 and 3 (pT217/T217 and pT205/T205 stages) was predictive of being A+T- and, at CSF stages 4 and 5 (MTBR-tau243 and total-tau stages) of being A+T+.

Finally, we investigated the prognostic capacity of our model for predicting progression to CDR $\geq$ 1 (AD dementia, progressors: 41/218) and CDR $\geq$ 0.5 (MCI or very mild AD dementia, progressors: 30/214). We found that CU (CDR=0) and very mild AD (CDR=0.5) participants at the highest CSF stages (4-5; MTBR-tau243 and total-tau stages) exhibited an increased risk (HR[95%CI]=6.9[3.0, 16.0], p<0.001) of progressing to AD dementia (CDR $\geq$ 1) at follow-up, even when adjusting for age, sex and clinical status (*i.e.*, CDR=0 or CDR=0.5) at baseline, compared to participants at CSF stages

1-3 (Fig. 6J-K and Supplementary Table 9). Similarly, CU participants at higher CSF stages (*i.e.*, 4-5) had higher risk (HR[95%CI]=4.2[2.0, 8.8], $p<0.001$) of progressing to very mild AD or more advanced disease stages when compared to participants at lower, but positive, CSF stages (1-3, Fig. 6L-M and Supplementary Table 9). In this case, participants at CSF stages 1-3 also showed significant higher risk to progress to CDR $\geq$ 0.5 than those at CSF stage 0 (HR[95%CI]=5.0[1.6, 15.0], $p=0.005$). There were no progressors to CDR $\geq$ 1 at CSF stage 0, which prevented us to compare this group to the others. Kaplan-Meier curves for each individual CSF stage are depicted in Ext Data Fig. 6.

Discussion

In this study, we created and evaluated a staging model for AD using five CSF biomarkers reflecting abnormalities of soluble A β and different soluble tau species. We have demonstrated that a single CSF collection is sufficient to accurately stage participants representing the entire AD *continuum*. This is possible because CSF biomarker abnormalities followed a stereotypical trajectory in all participants, which enabled a single staging model usable for everyone. Notably, we have been able to relate the CSF stages of our model to abnormality in other well-described AD biomarkers, such as A β -PET, tau-PET, MRI and in cognitive measures. Further, our CSF staging model was able to accurately predict positivity of the imaging biomarkers of A β and tau, and to predict A/T status, as assessed by PET. The CSF staging model was also related to cognitive stages and was able to differentiate cognitive impairment due to AD from other dementias. Importantly, we also observed different longitudinal rates of change of AD biomarkers at different CSF stages, which may allow us to determine which participants will progress more in key aspects of the disease. We also showed that participants in the more advanced stages of our CSF-based model were at higher risk for clinical decline. And, finally, we were able to replicate the model and main results in an independent cohort. Altogether, these results prove the validity and clinical utility of our CSF staging model, suggesting that it may hold promise for both clinical practice and in clinical trials⁴⁴.

The first aim of this analysis sought to establish whether there was a stereotypic ordering in when key CSF biomarkers become abnormal. SuStaln is an optimal approach to solve this question, as it allows the modelling of different trajectories, if existent, using cross-sectional data⁴¹, as has been successfully applied to imaging biomarkers^{35,36,45}. We observed that the CSF biomarkers investigated in this study became abnormal in a particular sequence, and more importantly, that this sequence

386 did not vary systematically across participants. This result is important by itself as it
387 tells us that there may be a single cascade of events that leads to sequential
388 abnormality of these soluble proteins in the brain, common to all AD patients. Previous
389 studies already suggested that changes in the levels of tau fragments phosphorylated
390 at different sites may be linked mechanistically and could be associated with disease
391 stages^{46–50}. Based on our results, A β plaques reflected by an imbalance of soluble
392 amyloid species (*i.e.*, low A β 42/40) may drive hyper-phosphorylation of tau in early
393 phosphorylation site (pT217/T217), as previously suggested by human and animal
394 data^{51,52}, which would subsequently be followed by hyper-phosphorylation in later site
395 (pT205/T205) and eventually increase other tau fragments (MTBR-tau243 and total
396 tau) due to tangles formation and neurodegeneration, respectively. Notably, this
397 sequence of events is in line with previous literature^{53,54}, and demonstrates that late
398 onset sporadic AD molecular pathway matches the same sequence of events as
399 autosomal dominant AD²⁹. Exploring in detail this cascade of events may provide
400 mechanistic insights into disease pathology and progression. And, in turn, could have
401 important consequences in drug development, as targeting some of the earliest events
402 of this sequence may stop or reduce subsequent events in the cascade and thereby
403 having a significant effect on tau aggregation^{46,50,55}.

404 Nonetheless, perhaps the most important result of our study was proving the utility of a
405 CSF model as a method to stage AD *in vivo*⁴⁴. In our model, CSF stages could be
406 related to main molecular changes and clinical tipping points in the course of the
407 disease, including abnormal levels of deposited A β (CSF stage 2:
408 pT217/T217)^{19,20,23,25,26,28,29,32} and tau (CSF stages 3: pT205/T205^{28,29,32}), early cognitive
409 impairment (CSF stage 4: MTBR-tau243³²) and neurodegeneration (CSF stage 5: total
410 tau⁴²), following the expected pattern. With the objective of characterizing the molecular
411 status of the participants using our model, we observed that participants at CSF stages
412 2 and 3 (pT217/T217 and pT205/T205 stages) could be categorized with high accuracy
413 as being A β -positive and tau-negative by PET (A+T-), while participants at CSF stage 4
414 (MTBR-tau243) or higher were A β - and tau-PET positive (A+T+)⁴². Importantly, these
415 cut-points were reproduced in the Knight-ADRC cohort, even using different PET
416 tracers and quantification methods supporting the consistency of the model. Being able
417 to accurately assess A β and tau status with a single CSF collection may be very useful
418 to select the optimal participants for a clinical trial, such as has been done in the
419 donanemab trial (NCT03367403)¹¹, without the need of acquiring both an A β -PET and
420 tau-PET scan to determine if a patient is eligible for treatment. In BioFINDER-2, we
421 also observed the diagnostic utility of this CSF staging model, as it was able to
422 accurately discern AD from non-AD related cognitive impairment, and could

differentiate cognitive stages. Thus, the use of our model as a diagnostic tool may have important consequences also at the clinical level.

Notably, our CSF staging model also showed prognostic utility. First, we observed that participants at different CSF stages showed different rates of change in multiple biomarkers. For instance, rates of A β accumulation across CSF stages showed the previously reported inverted U shape^{3,56}, with participants at CSF stage 2 (pT217/T217) exhibiting the highest rates of change. On the other hand, the other imaging biomarkers and cognitive scores showed increased rate of change with increasing CSF stages, only plateauing at the last stage, as expected⁵⁷. These results support the use of our staging model as an enrichment technique for clinical trials⁵⁸. But, more importantly, we also observed that the CSF staging model was able to predict clinical progression. Being at the later stages of our model, increased the risk of progressing to AD dementia, even when accounting for cognitive status at baseline (Fig. 5). Further, we also observed a higher risk of progressing to MCI or very mild AD, although this analysis should be replicated in larger cohorts with longer follow-up. Notably, the prognostic ability of our CSF staging model was replicated in the Knight-ADRC cohort. These results suggest a clear prognostic utility on staging participants based on their CSF profile, which may imply significant reductions in costs and complexity compared to previous staging methods based on PET^{34,36,37,59}.

Importantly, we view the present model as a first step toward providing meaningful disease progression staging using a single CSF measurement⁴⁴. We expect that additional biomarkers will be included to the model to either gain further granularity in specific disease stages, or to signify to other pathophysiological events (*e.g.*, microglial reactivity)⁶⁰. Being able to measure several pathophysiological abnormalities using one sample is one of the main advantages of using fluid samples instead of PET for staging. Another advantage of this model is that financial and infrastructure cost of CSF is low compared to other measures, such as PET. Looking toward the future, we hope to be able translate these results into plasma biomarkers, which would facilitate even greater availability and cost-effectiveness. Widespread use of our fluid biomarker staging model in primary care would likely require replacing CSF measures with plasma measures without greatly sacrificing model performance. Efforts in this direction are currently underway, but development of reliable plasma assays for pT205/T205 and MTBR-tau243 are still ongoing.

This study has several strengths but also some limitations. The main strength of this study is the proven utility of the model, which was replicated in an independent cohort, and thereby supports the generalizability of our staging model. Another important strength is the use of several biomarkers measured with very high-performing

assays^{28,61}, which is crucial for the accurate assessment of pathology⁴. However, some limitations must be recognized. Although we included CSF biomarkers with proven utility, we acknowledge that there are some other interesting markers, such as p-tau235⁶², that have not been analyzed in this study. However, we think that our CSF staging model in its current form was still successful at signaling the main inflection points of the disease. Further, p-tau231, which is thought to become abnormal early in the disease²⁰⁻²², although not always^{25,61}, was excluded from our model as it followed a similar abnormality tendency as pT217/T217, without providing better performance for staging than the later. We hypothesize that this may be in part related to difference in analytical performances, as the mass spectrometry platform used in our study provided rather higher coefficient of variation for pT231/T231 measurements (12-18% compared to 5-7% for pT217/T217). Future studies in earlier cohorts or with optimized assays for measuring p-tau231 should test whether the present model could be improved. Another important issue is that we acknowledge that CSF collection require trained clinicians, and we plan to move towards a plasma-based staging models when these biomarkers become available. A replication of these results in a more diverse population is also needed to confirm the utility of our model in a less selected population. We would also like to point out that the CSF stages proposed here are related to events of the disease and not to time. Thus, it may be possible that the time for progressing from one CSF stage to the next vary significantly depending on the CSF stage at baseline.

In conclusion, in this study we have developed an accurate staging model for AD based on only five CSF biomarkers, and we have evaluated it in two large independent cohorts. We have shown that the model is stable, and accurately reflects biomarker changes in AD, providing an easier and cheaper method for characterization of participants for both clinical setting and trials. Further, our model has demonstrated its utility for prognosis, being able to identify participants with more pronounced longitudinal changes in AD biomarkers as well as those individuals with higher risk of deteriorating in cognitive status. This CSF staging model may be a useful, cheap, and accessible method in clinical trials for optimal selection of study participants and as a surrogate outcome measure. Further, the staging model has great potential for use in clinical practice in the diagnostic and prognostic work-up of patients with cognitive symptoms and potentially also for selecting optimal candidates for disease-modifying treatments. And we expect it may have an influence on the update of the A/T/(N) criteria.⁴² Altogether, our staging model may be an important step towards a more sophisticated personalized medicine approach of AD, which will be key with the advancement of novel disease-modifying treatments.

497 DATA AVAILABILITY:

498 The datasets generated and/or analyzed during the current study are available from the
499 authors (O.H and R.J.B). We will share datasets within the restrictions of IRB ethics
500 approvals, upon reasonable request.

501 For BioFINDER-2 data, anonymized data will be shared by request from a qualified
502 academic investigator for the sole purpose of replicating procedures and results
503 presented in the article and as long as data transfer is in agreement with EU legislation
504 on the general data protection regulation and decisions by the Ethical Review Board of
505 Sweden and Region Skåne, which should be regulated in a material transfer
506 agreement.

507

508

509 DISCLOSURES

510 OH has acquired research support (for the institution) from ADx, AVID
511 Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and
512 Roche. In the past 2 years, he has received consultancy/speaker fees from AC
513 Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio,
514 Genentech, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. JWV is
515 supported by the SciLifeLab & Wallenberg Data Driven Life Science Program (grant:
516 KAW 2020.0239). KH is an Eisai-sponsored voluntary research associate professor at
517 Washington University and has received salary from Eisai. Washington University,
518 RJB, and DMH have equity ownership interest in C2N Diagnostics. RJB. and DMH
519 receive income from C2N Diagnostics for serving on the scientific advisory board. KH,
520 NRB, and RJB. may receive income based on technology (METHODS TO DETECT
521 MTBR TAU ISOFORMS AND USE THEREOF) licensed by Washington University to
522 C2N Diagnostics. DMH may receive income based on technology (ANTIBODIES TO
523 MID-DOMAIN OF TAU) licensed by Washington University to C2N Diagnostics. RJB
524 has received honoraria as a speaker, consultant, or advisory board member from
525 Amgen and Roche. DMH is on the scientific advisory board of Genentech, Denali, and
526 Cajal Neurosciences, and consults for Alector and Asteroid. NRB is co-inventor on the
527 following US patent applications: 'Methods to detect novel tau species in CSF and use
528 thereof to track tau neuropathology in Alzheimer's disease and other tauopathies'
529 (PCT/US2020/046224); 'CSF phosphorylated tau and amyloid beta profiles as
530 biomarkers of tauopathies' (PCT/US2022/022906); and 'Methods of diagnosing and
531 treating based on site-specific tau phosphorylation' (PCT/US2019/030725). NRB may
532 receive a royalty income based on technology licensed by Washington University to
533 C2N Diagnostics.

534

535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572

FUNDING

The BioFINDER study was supported by the Swedish Research Council (2022-00775), ERA PerMed (ERAPERMED2021-184), the Knut and Alice Wallenberg foundation (2017-0383), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, the Swedish Alzheimer Foundation (AF-980907), the Swedish Brain Foundation (FO2021-0293), The Parkinson foundation of Sweden (1412/22), the Cure Alzheimer's fund, the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, the Skåne University Hospital Foundation (2020-O000028), Regionalt Forskningsstöd (2022-1259) and the Swedish federal government under the ALF agreement (2022-Projekt0080). The precursor of ^{18}F -flutemetamol was sponsored by GE Healthcare. The precursor of ^{18}F -RO948 was provided by Roche. GS received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie action grant agreement No 101061836, from an Alzheimer's Association Research Fellowship (#AARF-22-972612), Greta och Johan Kocks research grants and, travel grants from the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University.

This work was supported by resources and effort provided by the Tracy Family SILQ Center (PI: RJB) established by the Tracy Family, Richard Frimel and Gary Werths, GHR Foundation, David Payne, and the Willman Family brought together by The Foundation for Barnes-Jewish Hospital. This work was also supported by resources and effort provided by the Hope Center for Neurological Disorders and the Department of Neurology at the Washington University School of Medicine. This work was also supported by the Clinical, Fluid Biomarker, and Imaging Cores of the Knight ADRC (P30 AG066444 [PI: JCM], P01 AG03991 [PI: JCM], and P01 AG026276 [PI: JCM]) at the Washington University School of Medicine for participant evaluation, samples, and data collection. The mass spectrometry analyses of BioFINDER-2 and Knight ADRC samples were supported by Eisai industry grant to Washington University (PI: KH and RJB) and the Knight ADRC developmental project (PI: NRB) and R01AG070941 (PI: SES).

The funding sources had no role in the design and conduct of the study; in the collection, analysis, interpretation of the data; or in the preparation, review, or approval of the manuscript.

573

574

575 References

- 576 1. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global
577 prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis
578 for the Global Burden of Disease Study 2019. *Lancet Public Health* **7**, e105–e125
579 (2022).
- 580 2. Scheltens, P. *et al.* Alzheimer's disease. *Lancet* **388**, 505–17 (2016).
- 581 3. Villemagne, V. L. *et al.* Amyloid- β deposition, neurodegeneration, and cognitive
582 decline in sporadic Alzheimer's disease: A prospective cohort study. *Lancet*
583 *Neurol* **12**, 357–367 (2013).
- 584 4. Hansson, O. Biomarkers for neurodegenerative diseases. *Nature Medicine* vol.
585 27 954–963 Preprint at <https://doi.org/10.1038/s41591-021-01382-x> (2021).
- 586 5. Leuzy, A. *et al.* Biomarker-Based Prediction of Longitudinal Tau Positron
587 Emission Tomography in Alzheimer Disease. *JAMA Neurol* **79**, 149 (2022).
- 588 6. Mattsson-Carlsson, N. *et al.* Prediction of Longitudinal Cognitive Decline in
589 Preclinical Alzheimer Disease Using Plasma Biomarkers. *JAMA Neurol* (2023)
590 doi:10.1001/jamaneurol.2022.5272.
- 591 7. Salvadó, G. *et al.* Optimal combinations of CSF biomarkers for predicting
592 cognitive decline and clinical conversion in cognitively unimpaired participants
593 and mild cognitive impairment patients: A multi-cohort study. *Alzheimer's &*
594 *Dementia* (2023) doi:10.1002/alz.12907.
- 595 8. Ossenkoppele, R. *et al.* Accuracy of Tau Positron Emission Tomography as a
596 Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. *JAMA Neurol*
597 **78**, 961 (2021).
- 598 9. van Dyck, C. H. *et al.* Lecanemab in Early Alzheimer's Disease. *New England*
599 *Journal of Medicine* **388**, 9–21 (2023).
- 600 10. Cummings, J. *et al.* Aducanumab: Appropriate Use Recommendations Update. *J*
601 *Prev Alzheimers Dis* (2022) doi:10.14283/jpad.2022.34.
- 602 11. Mintun, M. A. *et al.* Donanemab in Early Alzheimer's Disease. *New England*
603 *Journal of Medicine* **384**, 1691–1704 (2021).
- 604 12. Mielke, M. M. *et al.* Performance of plasma phosphorylated tau 181 and 217 in
605 the community. *Nat Med* **28**, 1398–1405 (2022).
- 606 13. Thijssen, E. H. *et al.* Plasma phosphorylated tau 217 and phosphorylated tau 181
607 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a
608 retrospective diagnostic performance study. *Lancet Neurol* **20**, 739–752 (2021).
- 609 14. Thijssen, E. H. *et al.* Diagnostic value of plasma phosphorylated tau181 in
610 Alzheimer's disease and frontotemporal lobar degeneration. *Nat Med* **26**, 387–
611 397 (2020).
- 612 15. Suárez-calvet, M. *et al.* Novel tau biomarkers phosphorylated at T 181 , T 217 ,
613 or T 231 rise in the initial stages of the preclinical Alzheimer ' s continuum when
614 only subtle changes in A β pathology are detected. *EMBO Mol Med* 1–19 (2020)
615 doi:10.15252/emmm.202012921.
- 616 16. Karikari, T. K. *et al.* Blood phosphorylated tau 181 as a biomarker for Alzheimer's
617 disease: a diagnostic performance and prediction modelling study using data
618 from four prospective cohorts. *Lancet Neurol* **19**, 422–433 (2020).
- 619 17. Brier, M. R. *et al.* *Tau and Ab imaging, CSF measures, and cognition in*
620 *Alzheimer's disease*. <https://www.science.org>.

- 621 18. Janelidze, S. *et al.* Associations of Plasma Phospho-Tau217 Levels with Tau
622 Positron Emission Tomography in Early Alzheimer Disease. *JAMA Neurol* **78**,
623 149–156 (2021).
- 624 19. Palmqvist, S. *et al.* Discriminative Accuracy of Plasma Phospho-tau217 for
625 Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA* **324**, 772–781
626 (2020).
- 627 20. Milà-Alomà, M. *et al.* Plasma p-tau231 and p-tau217 as state markers of
628 amyloid- β pathology in preclinical Alzheimer's disease. *Nat Med* **28**, 1797–1801
629 (2022).
- 630 21. Ashton, N. J. *et al.* Plasma p-tau231: a new biomarker for incipient Alzheimer's
631 disease pathology. *Acta Neuropathol* **141**, 709–724 (2021).
- 632 22. Ashton, N. J. *et al.* Cerebrospinal fluid p-tau231 as an early indicator of emerging
633 pathology in Alzheimer's disease. *EBioMedicine* **76**, 103836 (2022).
- 634 23. Therriault, J. *et al.* Association of Phosphorylated Tau Biomarkers With Amyloid
635 Positron Emission Tomography vs Tau Positron Emission Tomography. *JAMA*
636 *Neurol* (2022) doi:10.1001/jamaneurol.2022.4485.
- 637 24. Murray, M. E. *et al.* Global neuropathologic severity of Alzheimer's disease and
638 locus coeruleus vulnerability influences plasma phosphorylated tau levels. *Mol*
639 *Neurodegener* **17**, 85 (2022).
- 640 25. Salvadó, G. *et al.* Specific associations between plasma biomarkers and
641 postmortem amyloid plaque and tau tangle loads. *EMBO Mol Med* (2023)
642 doi:10.15252/emmm.202217123.
- 643 26. Mattsson-Carlsson, N. *et al.* Longitudinal plasma p-tau217 is increased in early
644 stages of Alzheimer's disease. *Brain* **143**, 3234–3241 (2020).
- 645 27. Ashton, N. J. *et al.* Differential roles of A β 42/40, p-tau231 and p-tau217 for
646 Alzheimer's trial selection and disease monitoring. *Nat Med* (2022)
647 doi:10.1038/s41591-022-02074-w.
- 648 28. Barthélemy, N. R., Saef, B., Li, Y. & Gordon, B. A. The relationships of CSF tau
649 phosphorylation with amyloid PET, tau PET, and symptomatic Alzheimer
650 disease. *Nat Med* (2023).
- 651 29. Barthélemy, N. R. *et al.* A soluble phosphorylated tau signature links tau,
652 amyloid and the evolution of stages of dominantly inherited Alzheimer's
653 disease. *Nat Med* **26**, 398–407 (2020).
- 654 30. Gobom, J. *et al.* Antibody-free measurement of cerebrospinal fluid tau
655 phosphorylation across the Alzheimer's disease continuum. *Mol Neurodegener*
656 **17**, 81 (2022).
- 657 31. Horie, K., Barthélemy, N. R., Sato, C. & Bateman, R. J. CSF tau microtubule
658 binding region identifies tau tangle and clinical stages of Alzheimer's disease.
659 *Brain* **144**, 515–527 (2021).
- 660 32. Horie, K. *et al.* CSF MTBR-tau243 is a specific biomarker of tau pathology in
661 Alzheimer's disease.
- 662 33. Grothe, M. J. *et al.* In vivo staging of regional amyloid deposition. *Neurology* **89**,
663 2031–2038 (2017).
- 664 34. Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J. & Hansson, O. Staging β -
665 Amyloid Pathology with Amyloid Positron Emission Tomography. *JAMA Neurol*
666 **76**, 1319–1329 (2019).

- 667 35. Collij, L. E. *et al.* Multitracer model for staging cortical amyloid deposition using
668 PET imaging. *Neurology* **95**, e1538–e1553 (2020).
- 669 36. Vogel, J. W. *et al.* Four distinct trajectories of tau deposition identified in
670 Alzheimer’s disease. *Nat Med* **27**, 871–881 (2021).
- 671 37. Pascoal, T. A. *et al.* 18F-MK-6240 PET for early and late detection of
672 neurofibrillary tangles. *Brain* **143**, 2818–2830 (2020).
- 673 38. Therriault, J. *et al.* Biomarker modeling of Alzheimer’s disease using PET-based
674 Braak staging. *Nat Aging* **2**, 526–535 (2022).
- 675 39. Ferreira, D., Nordberg, A. & Westman, E. Biological subtypes of Alzheimer
676 disease. *Neurology* **94**, 436–448 (2020).
- 677 40. Murray, M. E. *et al.* Neuropathologically defined subtypes of Alzheimer’s disease
678 with distinct clinical characteristics: a retrospective study. *Lancet Neurol* **10**,
679 785–796 (2011).
- 680 41. Young, A. L. *et al.* Uncovering the heterogeneity and temporal complexity of
681 neurodegenerative diseases with Subtype and Stage Inference. *Nat Commun* **9**,
682 4273 (2018).
- 683 42. Jack, C. R. *et al.* A/T/N: An unbiased descriptive classification scheme for
684 Alzheimer disease biomarkers. *Neurology* **87**, 539–547 (2016).
- 685 43. Cho, H. *et al.* In vivo cortical spreading pattern of tau and amyloid in the
686 Alzheimer disease spectrum. *Ann Neurol* **80**, 247–258 (2016).
- 687 44. Therriault, J. *et al.* Staging of Alzheimer’s disease: past, present, and future
688 perspectives. *Trends in Molecular Medicine* vol. 28 726–741 Preprint at
689 <https://doi.org/10.1016/j.molmed.2022.05.008> (2022).
- 690 45. Archetti, D. *et al.* Inter-cohort validation of sustain model for alzheimer’s
691 disease. *Front Big Data* **4**, (2021).
- 692 46. Wesseling, H. *et al.* Tau PTM Profiles Identify Patient Heterogeneity and Stages
693 of Alzheimer’s Disease. *Cell* **183**, 1699–1713.e13 (2020).
- 694 47. Augustinack, J. C., Schneider, A., Mandelkow, E. M. & Hyman, B. T. Specific tau
695 phosphorylation sites correlate with severity of neuronal cytopathology in
696 Alzheimer’s disease. *Acta Neuropathol* **103**, 26–35 (2002).
- 697 48. Zheng-Fischhöfer, Q. *et al.* Sequential phosphorylation of Tau by glycogen
698 synthase kinase-3 β and protein kinase A at Thr212 and Ser214 generates the
699 Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-
700 filament-like conformation. *Eur J Biochem* **252**, 542–52 (1998).
- 701 49. Luna-Muñoz, J., Chávez-Macías, L., García-Sierra, F. & Mena, R. Earliest Stages of
702 Tau Conformational Changes are Related to the Appearance of a Sequence of
703 Specific Phospho-Dependent Tau Epitopes in Alzheimer’s Disease1. *Journal of*
704 *Alzheimer’s Disease* **12**, 365–375 (2007).
- 705 50. Stefanoska, K. *et al.* Alzheimer’s disease: Ablating single master site abolishes
706 tau hyperphosphorylation. *Sci. Adv* vol. 8 <https://www.science.org> (2022).
- 707 51. Mattsson-Carlsson, N. *et al.* Soluble P-tau217 reflects amyloid and tau pathology
708 and mediates the association of amyloid with tau. *EMBO Mol Med* **13**, (2021).
- 709 52. Mattsson-Carlsson, N. *et al.* A β deposition is associated with increases in soluble
710 and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease.
711 *Sci Adv* **6**, (2020).
- 712 53. Bateman, R. J. *et al.* Clinical and Biomarker Changes in Dominantly Inherited
713 Alzheimer’s Disease. *New England Journal of Medicine* **367**, 795–804 (2012).

54. Jack, C. R. Jr. *et al.* Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurology* **68**, 497–501 (2013).
55. Bancher, C. *et al.* Accumulation of abnormally phosphorylated τ precedes the formation of neurofibrillary tangles in Alzheimer's disease. *Brain Res* **477**, 90–99 (1989).
56. Jack, C. R. *et al.* Brain β -amyloid load approaches a plateau. *Neurology* **80**, 890–896 (2013).
57. Krishnadas, N. *et al.* Rates of regional tau accumulation in ageing and across the Alzheimer's disease continuum: an AIBL 18F-MK6240 PET study. *EBioMedicine* **88**, 104450 (2023).
58. Ossenkoppele, R., van der Kant, R. & Hansson, O. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials. *Lancet Neurol* (2022) doi:10.1016/S1474-4422(22)00168-5.
59. Collij, L. E. *et al.* Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent. *Eur J Nucl Med Mol Imaging* (2021) doi:10.1007/s00259-020-05174-2.
60. Hampel, H. *et al.* Developing the ATX(N) classification for use across the Alzheimer disease continuum. *Nat Rev Neurol* **17**, 580–589 (2021).
61. Janelidze, S. *et al.* Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease. (2022).
62. Lantero-Rodriguez, J. *et al.* P-tau235: a novel biomarker for staging preclinical Alzheimer's disease. *EMBO Mol Med* **13**, (2021).
63. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. (American Psychiatric Association, 2013). doi:10.1176/appi.books.9780890425596.
64. Jack, C. R. *et al.* NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's & Dementia* **14**, 535–562 (2018).
65. Morris, J. C. The clinical dementia rating (cdr): Current version and scoring rules. *Neurology* **43**, 2412–2414 (1993).
66. Folstein, M. F., Folstein, S. E. & McHugh, P. R. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* **12**, 189–198 (1975).
67. Morris, J. C. *et al.* The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers. *Alzheimer Dis Assoc Disord* **20**, 210–216 (2006).
68. Wisch, J. K. *et al.* Proteomic clusters underlie heterogeneity in preclinical Alzheimer's disease progression. *Brain* (2022) doi:10.1093/brain/awac484.
69. Aschenbrenner, A. J. *et al.* Comparison of plasma and CSF biomarkers in predicting cognitive decline. *Ann Clin Transl Neurol* **9**, 1739–1751 (2022).
70. Jack, C. R. *et al.* Defining imaging biomarker cut points for brain aging and Alzheimer's disease. *Alzheimer's and Dementia* **13**, 205–216 (2017).
71. Jack, C. R. *et al.* Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. *Brain* **138**, 3747–3759 (2015).
72. Dincer, A. *et al.* APOE ϵ 4 genotype, amyloid- β , and sex interact to predict tau in regions of high APOE mRNA expression. *Sci Transl Med* **14**, (2022).

761 73. Klunk, W. E. *et al.* The Centiloid project: Standardizing quantitative amyloid
762 plaque estimation by PET. *Alzheimer's and Dementia* **11**, 1-15.e4 (2015).
763 74. Su, Y. *et al.* Comparison of Pittsburgh compound B and florbetapir in
764 cross-sectional and longitudinal studies. *Alzheimer's & Dementia: Diagnosis,
765 Assessment & Disease Monitoring* **11**, 180–190 (2019).
766 75. Armitage, S. G. An analysis of certain psychological tests used for the evaluation
767 of brain injury. *Psychol Monogr* **60**, i–48 (1946).
768 76. Donohue, M. C. *et al.* The Preclinical Alzheimer Cognitive Composite: Measuring
769 Amyloid-Related Decline. *JAMA Neurol* **71**, 961–970 (2014).
770 77. Kaplan, E., Goodglass, H. & Weintraub, S. Boston naming test.
771 78. Grober, E., Buschke, H., Crystal, H., Bang, S. & Dresner, R. Screening for
772 dementia by memory testing. *Neurology* **38**, 900–903 (1988).
773 79. Fonteijn, H. M. *et al.* An event-based model for disease progression and its
774 application in familial Alzheimer's disease and Huntington's disease.
775 *Neuroimage* **60**, 1880–1889 (2012).
776 80. Young, A. L. *et al.* A data-driven model of biomarker changes in sporadic
777 Alzheimer's disease. *Brain* **137**, 2564–2577 (2014).
778 81. Aksman, L. M. *et al.* pySuStaln: A Python implementation of the Subtype and
779 Stage Inference algorithm. *SoftwareX* **16**, 100811 (2021).
780 82. Kass, R. E. & Raftery, A. E. Bayes Factors. *J Am Stat Assoc* **90**, 773 (1995).
781 83. Hosmer, D. W., Lemeshow, S. & Sturdivant, R. X. *Applied Logistic Regression*.
782 (Wiley, 2013). doi:10.1002/9781118548387.
783
784

785 Online methods

786 Participants

787 *BioFINDER-2*

788 We assessed 426 participants from the Swedish BioFINDER-2 study
 789 (NCT03174938)¹⁹, with the complete set of CSF biomarkers available. Participants
 790 were recruited at Skåne University Hospital and the Hospital of Ängelholm in Sweden.
 791 These participants also had amyloid-PET (n=251), tau-PET (n=417), a magnetic
 792 resonance imaging (MRI, n=420) and cognitive assessment (n=426). Also, 220
 793 participants had available CSF biomarkers at follow-up (mean time (SD) = 2.05(0.22)
 794 years). Inclusion and exclusion criterion for this study has been detailed before¹⁹. In
 795 summary, CU participants do not fulfil criteria for MCI or dementia according to DSM-
 796 5⁶³. Subjective cognitive decline (SCD) participants were considered as CU, in
 797 accordance with the research framework by the National Institute on Aging-Alzheimer's
 798 Association⁶⁴. MCI participants had a MMSE score above 23, they did not fulfil the
 799 criteria for major neurocognitive disorder (dementia) according to DSM-5 and
 800 performed worse than -1.5 SD in at least one cognitive domain according to age and
 801 education stratified test norms. AD dementia was diagnosed according to the DSM-5
 802 criteria for major neurocognitive disorder due to AD and an abnormal biomarker for A β
 803 pathology was also required. Participants fulfilling the criteria for any other dementia
 804 were categorized as non-AD dementias, as previously described.¹⁹

805 *Knight-ADRC*

806 Knight ADRC cohort consisted of community-dwelling volunteers enrolled in studies of
 807 memory and aging at Washington University in St. Louis. All Knight ADRC participants
 808 underwent a comprehensive clinical assessment that included a detailed interview of a
 809 collateral source, a neurological examination of the participant, the Clinical Dementia
 810 Rating (CDR[®])⁶⁵ and the MMSE⁶⁶. Individuals with a CDR of 0.5 or greater were
 811 considered to have a dementia syndrome and the probable aetiology of the dementia
 812 syndrome was formulated by clinicians based on clinical features in accordance with
 813 standard criteria and methods⁶⁷. In Knight-ADRC cohort, participants were categorized
 814 as CU if they were scored CDR=0, either A β negative or positive (CU- and CU+,
 815 respectively); very mild AD patients (CDR=0.5); and mild AD dementia patients
 816 (CDR $\geq$ 1) if clinical syndrome was typical of symptomatic AD. Participants with
 817 CDR $\geq$ 0.5 with different aetiology were assessed as being other dementia patients
 818 regardless of their amyloid status.

819 All participants gave written informed consent and ethical approval was granted by the
 820 Regional Ethical Committee in Lund, Sweden and the Washington University Human
 821 Research Protection Office, respectively.

822

823 Fluid biomarkers

824 Measurement of CSF tau species (*i.e.*, pT205/T205, pT217/T217, pT231/T231, MTBR-
825 tau243 and total-tau [the residue 151-153]) was performed at Washington University in
826 both cohorts using the newly developed IP/MS method, as previously detailed³². In
827 BioFINDER-2, CSF levels of A β 42/40 and NfL were measured using the Elecsys
828 platform as previously explained¹⁹. A β positivity was assessed using CSF A β 42/40
829 (<0.080), unless otherwise stated, based on Gaussian-mixture modeling. In Knight-
830 ADRC, CSF A β 42/40 levels were measured as explained previously^{28,68}. The CSF A β 42/40
831 positivity threshold (0.0673) had the maximum combined sensitivity and specificity in
832 distinguishing amyloid-PET status. CSF NfL was measured with a commercial ELISA kit
833 (UMAN Diagnostics, Umea, Sweden), as explained previously⁶⁹.

834

835 Image acquisition and processing

836 Image acquisition and processing details from BioFINDER-2 have been previously
837 reported¹⁹. In brief, amyloid- and tau-PET were acquired using [¹⁸F]flutemetamol and
838 [¹⁸F]RO948, respectively. Amyloid-PET binding was measured as SUVR using a
839 neocortical meta-ROI, and with the cerebellar grey as a reference region. Of note, most
840 of the AD dementia patients did not undergo amyloid-PET in BioFINDER-2, due to the
841 study design. For main analyses, tau-PET binding was measured in a temporal meta-
842 ROI⁷⁰, which included, entorhinal, amygdala, parahippocampal, fusiform, inferior
843 temporal, and middle temporal ROIs, using the inferior cerebellar cortex as reference
844 region without partial volume correction. Additionally, tau-PET binding was also
845 measured in regions covering early (Braak I), intermediate (Braak III-IV) and late
846 (Braak V-VI) tau deposition areas⁴³. For assessing cortical thickness, T1-weighted
847 anatomical magnetization-prepared rapid gradient echo (MPRAGE) images (1mm
848 isotropic voxels) were used. A cortical thickness meta-ROI was calculated including
849 entorhinal, inferior temporal, middle temporal, and fusiform using FreeSurfer (v.6.0.
850 <https://surfer.nmr.mgh.harvard.edu>) parcellation, which are areas known to be
851 susceptible to AD-related atrophy⁷¹.

852 Methodological details for imaging processing and quantification for the Knight-ADRC
853 cohort have been also previously reported^{71,72}. In brief, MPRAGE data were processed
854 using Freesurfer (v.5.3) to generate regions of interest. Amyloid-PET was acquired with
855 either [¹¹C]PIB or [¹⁸F]florbetapir and was quantified in a neocortical meta-ROI using
856 cerebellar grey as a reference region. SUVR values were transformed to Centiloids⁷³ to
857 allow direct comparison between tracers using previously validated transformations⁷⁴.
858 [¹⁸F]flortaucipir ([¹⁸F]AV1451) was used as a tau-PET tracer and images were

quantified in the same temporal meta-ROI as in BioFINDER-2 and assessed as positive if SUVR>1.32 based on previous work. The same additional regions as in BioFINDER-2 were also used to quantify tau-PET binding in early, intermediate, and late tau deposition regions. In all cases, cerebellar grey was used as a reference region. T1-weighted images were used to measure cortical thickness using the same approach as is in the BioFINDER-2 cohort.

Neuropsychological testing

mPACC and a global cognitive composite were used as the main cognitive outcome in BioFINDER-2 and Knight-ADRC participants, respectively. In BioFINDER-2 participants, the mPACC-5 composite was calculated using mean of z-scores of Alzheimer's disease assessment scale (ADAS) delayed recall (weighted double), animal fluency, MMSE⁶⁶, and trail making test-A (TMT-A)⁷⁵, as a sensitive measure of early cognitive impairment⁷⁶. Z-scores were calculated with a group of CU- as reference. Further, we also calculated several cognitive composites averaging z-scores of different cognitive tests. For the memory composite we used ADAS delayed and immediate word recall; for the executive function composite, we used TMT-A, TMT-B and symbol digit test; for the language composite we used the animal fluency test and the Boston naming test total score (BNT)⁷⁷; and, finally for the visuo-spatial composite we used the visual object and space perception (VOSP) cube and letters tests.

In Knight-ADRC, the global cognitive composite was created using mean of z-scores of free and cued selective reminding test (FCSRT) free recall⁷⁸, animal fluency, TMT-A and TMT-B. Z-scores were also calculated from a CU- group as a reference. For the executive function composite, we used TMT-A and TMT-B. We could not obtain any other cognitive composite similar to those derived in BioFINDER-2, due to lack of similar tests. However, we selected individual tests to try to recapitulate similar cognitive measures. For memory we used FCSRT, and for language we used animal fluency. No tests were available related visuo-spatial capacity.

Model creation

Model development was done with SuStaln⁴¹ using cross-sectional data of amyloid-positive participants based on CSF A β 42/40 levels. We selected these participants because we wanted to create a staging model focused on AD. SuStaln is a machine-learning technique that unravels temporal progression patterns (stages) allowing for multiple different trajectories (subtypes). For our purpose, we used the event-based model⁷⁹ (or mixture SuStaln⁸⁰), in which the input data is the probability of each biomarker of being abnormal for each participant. In our case, we used a Gaussian-

mixture modelling approach (with 2 Gaussians) to obtain these probabilities. With this information, SuStaln provides the maximum likelihood sequence by which biomarkers become abnormal, and gives a probability for this ordering, for all subtypes. The number of SuStaln stages is defined by the number of biomarkers provided to the model (*i.e.*, one per biomarker plus a biomarker negative stage). The selection of the optimal number was determined using cross-validation, optimizing on cross-validation based information criterion (CVIC) and out-of-sample log-likelihood was calculated. The optimal number of subtypes was then selected based on these criteria, using the minimal number of subtypes that had the lowest CVIC and higher log-likelihood⁴¹. In this study, we used pySuStaln⁸¹, a Python implementation of the original method (downloaded 08/2022).

In our initial model with BioFINDER-2 participants, we included all biomarkers available and performed the cross-correlation in models with one, two and three subtypes. Although CVIC measures were lower in the three subtypes model, the similar log-likelihood in all three models, supported the one subtype model as the optimal one due to its lower complexity⁸². Upon examining the outcome of this model, we observed that pT217/T217, pT231/T231, and pT181/T181 position certainty was low, as they seemed to compete for the second position (Ext Data Fig. 1A). To avoid stages with low certainty, we decided to try to optimize this model through iterative removal of these biomarkers. All the possible combinations were created (*i.e.*, removing pT217/T217 and/or pT231/T231 and/or pT181/T181) and compared using the CVIC (Ext Data Fig. 1B). We observed that models including only one of these biomarkers (models 5-7) were better than those including two (models 2-4) or all three (model 1). Further, models including pT181/T181 performed worse, and those including pT217/T217 performed better. Thus, the optimal model was selected as that including only pT217/T217 (model 7). Once the biomarkers to be included in the model were selected, we repeated the cross-validation with models up to three subtypes. Comparing CVIC and log-likelihood values, we once again selected the one subtype model as the optimal (Ext Data Fig. 1C). Based on this cross-validated model, we then staged all BioFINDER-2 participants.

For Knight-ADRC, we created the model from the biomarkers selected in the BioFINDER-2 cohort. To investigate whether one subtype was also the selected model, we run SuStaln and created cross-validated models for one to three subtypes. Again, based on CVIC (subtypes: 1=578.9; 2=598.1; 3=611.0) and log-likelihood (mean: 1=-29.4; 2=-30.4; 3=-31.0), the less complex model (*i.e.*, one subtype) was selected as the optimal. We then staged all Knight-ADRC participants based on this cross-validated model.

As a sensitivity analysis, we compared the levels of the two biomarkers excluded (pT231/T231 and pT181/T181) with those of pT217/T217 in the optimal model. In summary, we observed that these biomarkers followed a similar trajectory across CSF stages as pT217/T217, although with lower increases in the two cohorts (Ext Data Fig. 8A-B), which supports our decision of removing them from the model to have more stable and independent stages.

Statistical analyses

All biomarkers were z-scored using participants older than 60 from the CU- group as a reference (BioFINDER-2: n=63 and Knight-ADRC: n=71). When necessary, biomarker data was inverted such that higher z-scores related to higher abnormality across all biomarkers. Differences in biomarkers by CSF stages were assessed using Kruskal-Wallis test. Wilcoxon-test was used for *post-hoc* comparisons adjusted for multiple comparisons with false discovery rate (FDR) correction (only differences in consecutive CSF stages are shown in figures). For categorical data (*i.e.*, sex, *APOE* carriership and diagnosis), we used chi-squared tests. LOESS regressions were used to fit the progression of biomarkers abnormalities across the CSF stages. ROC curves were used to assess the utility of CSF stages for predicting amyloid-PET, tau-PET positivity and to compare AD to non-AD objective cognitive impairment (MCI or dementia states). Maximization of Youden's index was used to select the optimal CSF stage cut-off in each case (*pROC* and *cutpointR* packages were used). For ordinal categories (*i.e.*, A/T status and diagnosis), ordinal logistic regression models were used (*MASS* and *lrm* packages). An equivalent measure to AUC, the c-index, was used to assess the performance of the CSF staging⁸³. Confidence intervals were calculated using bootstrapping. Predicted probabilities of the outcome groups per each CSF stages were calculated using the *predict* function, Longitudinal rates of changes were calculated for every participant using linear regression models. One participant with a very negative rate of change in amyloid-PET (z-score < -1.8) was considered an outlier by visual inspection and excluded from the analysis. Kaplan-Meier curves were used to assess clinical progression using *survival* and *survminer* packages. Cox-proportional hazards model were used to calculate the risk of clinical progression adjusting for age and sex in all cases, and further baseline clinical status if necessary. All analyses were performed with R (v.4.1.0). A two-sided p value < 0.05 was considered statistically significant.

969 Tables

	All (n=426)	CU- (n=80)	CU+ (n=79)	MCI+ (n=88)	ADD+ (n=100)	nonAD (n=79)
Age, years	71.5 (8.5)	70.7 (9.5)	71.1 (9.5)	72.0 (7.4)	73.0 (6.9)	70.2 (9.0)
Women, n(%)	211 (49.5%)	39 (48.8%)	40 (50.6%)	38 (43.2%)	56 (56.0%)	38 (48.1%)
APOE-ε4 carriershp, n(%) ^a	246 (57.7%)	26 (32.5%)	58 (73.4%)	62 (70.5%)	74 (74.0%)	26 (32.9%)
Years of education ^b	12.3 (3.8)	12.0 (3.2)	12.2 (3.4)	12.7 (4.5)	12.0 (4.0)	12.7 (3.5)
Amyloid-PET, Centiloids ^c	37.3 (44.2)	-4.48 (9.50)	41.8 (36.0)	69.6 (36.0)	115 (23.3)	5.67 (23.3)
Tau-PET, SUVR ^d	1.53 (0.61)	1.16 (0.08)	1.23 (0.21)	1.50 (0.45)	2.38 (0.58)	1.16 (0.10)
Cortical thickness, mm ^e	2.46 (0.16)	2.56 (0.09)	2.55 (0.12)	2.46 (0.13)	2.32 (0.15)	2.46 (0.18)
CSF NfL ^f	245 (175)	147 (79.1)	189 (153)	223 (128)	316 (180)	333 (222)
mPACC ^g	-1.62 (2.03)	0.06 (0.76)	-0.26 (0.78)	-1.88 (0.72)	-4.34 (1.72)	-1.69 (2.03)
Progressed to MCI	11 (2.6%)	0 (0%)	11 (13.9%)	-	-	-
Progressed to ADD+	41 (9.6%)	0 (0%)	3 (3.8%)	38 (43.2%)	-	-

970

971 Table 1: BioFINDER-2 participants' characteristics

972 Data is shown as mean(SD) unless otherwise stated. Participants are divided by
973 clinical diagnosis and amyloid status based on their CSF Aβ42/40 levels (Aβ+: <0.080).
974 Only participants who progressed to MCI or dementia patients due to AD etiology were
975 considered to progress.

976 ^a, 1 participant missing; ^b, 4 participants missing; ^c, 175 participants missing; ^d, 9
977 participants missing; ^e, 6 participants missing; ^f, 4 participants missing; ^g, 36
978 participants missing.

979 Abbreviations: Aβ, amyloid-β; AD, Alzheimer's disease; ADD+, Alzheimer's disease
980 dementia amyloid positive; CU-, cognitively unimpaired amyloid negative; CU+,
981 cognitively unimpaired amyloid positive; CSF, cerebrospinal fluid; MCI, mild cognitive
982 impairment amyloid positive; nonAD, non-Alzheimer's related disease; PET, positron
983 emission tomography; ROI, region of interest; SD, standard deviation; SUVR,
984 standardized uptake value ratio.

985

	All (n=222)	CU- (n=84)	CU+ (n=98)	Very mild AD (n=24)	AD dementia (n=9)	Other dementias (n=7)
Age, years	71.2 (7.7)	67.6 (7.2)	73.2 (7.4)	73.4 (6.4)	74.1 (7.6)	75.0 (7.2)
Women, n(%)	112 (50.5%)	39 (46.4%)	56 (57.1%)	9 (37.5%)	4 (44.4%)	4 (57.1%)
APOE-ε4 carriership, n(%) ^a	99 (44.6%)	18 (21.4%)	56 (57.1%)	15 (62.5%)	6 (66.7%)	4 (57.1%)
Years of education	16.3 (2.5)	16.5 (2.3)	16.5 (2.4)	14.9 (2.8)	14.7 (2.6)	17.7 (2.2)
Amyloid-PET, Centiloids	44.0 (41.2)	7.6 (11.2)	57.7 (33.3)	83.6 (23.7)	119 (38.3)	57.9 (46.8)
Tau-PET, SUVR ^b	1.24 (0.22)	1.13 (0.08)	1.22 (0.13)	1.51 (0.38)	1.72 (0.25)	1.23 (0.12)
Cortical thickness, mm	2.52 (0.16)	2.59 (0.12)	2.53 (0.14)	2.39 (0.17)	2.29 (0.15)	2.35 (0.19)
CSF NFL ^c	1000 (578)	740 (313)	1010 (489)	1660 (974)	1360 (404)	1230 (569)
Global cognitive composite, z- score ^d	0.44 (1.11)	-0.01 (0.72)	0.36 (0.75)	2.01 (0.96)	3.86 (2.36)	1.12 (1.40)
Progressed to CDR≥0.5 ^e	41 (18.5%)	8 (9.5%)	33 (33.7%)	-	-	-
Progressed to CDR≥1 ^f	30 (14.5%)	0 (0%)	14 (14.3%)	16 (66.7%)	-	-

Table 2: Knight-ADRC participants' characteristics

Data is shown as mean(SD) unless otherwise stated. Participants are divided by clinical diagnosis and amyloid status based on their CSF Aβ_{42/40} levels (Aβ₊: <0.0673). Very mild AD dementia patients had a CDR=0.5 and mild AD dementia patients had a CDR≥1, both with AD as etiology. Other dementias group includes participants with CDR>0 with non-AD etiology. Only participants who progressed to CDR≥0.5 or CDR≥1 due to AD etiology were considered to progress.

^a, 1 participant missing; ^b, 3 participants missing; ^c, 5 participants missing; ^d, 2 participants missing; ^e, 4 participants missing; ^f, 8 participants missing.

Abbreviations: Aβ, amyloid-β; AD, Alzheimer's disease; ADD+, Alzheimer's disease dementia amyloid positive; CU-, cognitively unimpaired amyloid negative; CU+, cognitively unimpaired amyloid positive; CSF, cerebrospinal fluid; MCI, mild cognitive impairment amyloid positive; mPACC, modified preclinical Alzheimer's cognitive composite; nonAD, non-Alzheimer's related disease; PET, positron emission tomography; ROI, region of interest; SD, standard deviation.

1003 **Figure captions**

1004 **Fig 1: CSF staging model**

1005 Description of the CSF staging model and the levels of the biomarkers included in the
1006 model by CSF stage. Cross-validated confusion matrix of the CSF biomarkers of the
1007 model is shown in A. Biomarkers are sorted by the time they become abnormal based
1008 on the results of SuStaln. Darkness represents the probability of that biomarker of
1009 becoming abnormal at that position, with black being 100%. Only amyloid-positive
1010 participants are included in this analysis. Individual biomarker levels by CSF stage in all
1011 BioFINDER-2 participants are shown in B. CSF levels are z-scored based on a group
1012 of CU- participants (n=63) and all increases represent increase in abnormality.
1013 Significant differences in contiguous CSF stages are shown with asterisks. Horizontal
1014 line is drawn at z-score=1.96 which represents 95%CI of the reference group (CU-).
1015 Smoothed LOESS lines of all CSF biomarkers are shown in C for comparison. CSF
1016 stage 0 represent being classified as normal by the model. Black dots and vertical lines
1017 represent mean and SD by CSF stage, respectively. *: p<0.05; **: p<0.01; ***: p<0.001.
1018 Abbreviations: A β , amyloid- β ; CI, confidence interval; CU-, cognitively unimpaired
1019 amyloid negative; CSF, cerebrospinal fluid; LOESS, locally estimated scatterplot
1020 smoothing; MTBR, microtubule binding region; pT, phosphorylated tau; SuStaln,
1021 subtype and stage inference.

1022

1023 **Fig 2: AD pathology, biomarkers and cognition by CSF stages**

1024 Depiction of individual biomarker levels, not used in the creation of the model, by CSF
1025 stage in BioFINDER-2 participants (A). These include biomarkers of amyloid (amyloid-
1026 PET) and tau (tau-PET in the meta-temporal ROI) pathologies, neurodegeneration
1027 (cortical thickness in the AD signature areas and CSF NfL) and cognition (mPACC).
1028 Biomarkers are z-scored based on a group of CU- participants (n=63) and all increases
1029 represent increase in abnormality. Significant differences in contiguous CSF stages are
1030 shown with asterisks. Horizontal line is drawn at z-score=1.96 which represents 95%CI
1031 of the reference group (CU-). Smoothed LOESS lines of all AD biomarkers are shown
1032 in B for comparison. All participants with available data were included in amyloid- and
1033 tau-PET analyses. For neurodegeneration (cortical thickness and NfL) and cognitive
1034 (mPACC) measures, we excluded non-AD dementia patients to avoid bias. Of note,
1035 only few AD dementia cases had amyloid-PET available due to study design. CSF
1036 stage 0 represent being classified as normal by the model. Black dots and vertical lines
1037 represent mean and SD per CSF stage, respectively. *: p<0.05; **: p<0.01; ***:
1038 p<0.001.

Abbreviations: A β , amyloid- β ; AD, Alzheimer's disease; CI, confidence interval; CU-, cognitively unimpaired amyloid negative; CSF, cerebrospinal fluid; LOESS, locally estimated scatterplot smoothing; mPACC, modified preclinical Alzheimer's cognitive composite; NfL, neurofilament light; PET, positron emission tomography; ROI, region of interest.

1044

Fig 3: CSF stages for predicting A/T status and cognitive stages

CSF stages for predicting pathological status as measured with PET is shown in A-B, and for predicting cognitive stages and diagnostic groups in C-D. Barplots represent the number of participants in each category per CSF stage. Numbers of participants in each category per CSF stage are shown within the barplots (A and C). In B and D, ROC curves were used to assess the classification into dichotomic categories (A β -PET, tau-PET and AD vs non-AD cognitive impairment), whereas ordinal logistic regressions were used for ordinal categories (A/T status and diagnosis). Heatmaps represent the predicted percentage of participants in each outcome category (A/T or diagnosis) by CSF stage. The most probable (highest percentage) category by CSF stage is framed in black. For ROC analyses, AUCs, sensitivity and specificity measures from these analyses are shown in the plot. The optimal cut-off in each case is shown as a vertical dashed line in A or C. An A-T+ participant (n=1) was excluded from the A/T status analysis. Non-AD dementia cases were excluded from the cognitive stages analysis. And, only patients with objective impairment (MCI or dementia) were included in the analyses of AD vs. non-AD. A β - and tau-PET were assessed as positive based on previously validated cut-offs (A β : SUVR>1.03, tau: SUVR>1.36).

Abbreviations: A β , amyloid- β ; AD, Alzheimer's disease; ADD+, Alzheimer's disease dementia amyloid-positive; A-T-, amyloid-negative tau-negative; A-T+, amyloid-negative tau-positive; A+T-, amyloid-positive tau-negative; A+T+, amyloid-positive tau-positive; CSF, cerebrospinal fluid; CU-, cognitively unimpaired amyloid-negative; CU+, cognitively unimpaired amyloid-positive; MCI+, mild cognitive impairment amyloid-positive; PET, positron emission tomography; ROC, receiver operating characteristic; ROI, region of interest; SUVR, standardized uptake value ratio.

1069

Fig 4: Longitudinal rate of change of AD biomarkers by CSF stages

Depiction of individual biomarker longitudinal rates of change by CSF stage in BioFINDER-2 participants (A). These include biomarkers of amyloid (amyloid-PET) and tau (tau-PET in the meta-temporal ROI) pathologies, neurodegeneration (cortical thickness in the AD signature) and cognition (mPACC). Biomarkers are z-scored based

on a group of CU- participants (n=63) and all increases represent increase in abnormality. Rates of change were calculated with individual linear regression models. Significant differences in contiguous CSF stages are shown with asterisks. Smoothed LOESS lines of all AD biomarkers are shown in B for comparison. All participants were included in amyloid- and tau-PET analyses. For neurodegeneration (cortical thickness) and cognitive (MMSE) measures, we excluded non-AD dementia patients to avoid bias. CSF stage 0 represent being classified as normal by the model. Black dots and vertical lines represent mean and SD per CSF stage, respectively. *: $p < 0.05$; **: $p < 0.01$; ***: $p < 0.001$.

Abbreviations: A β , amyloid- β ; AD, Alzheimer's disease; CI, confidence interval; CU-, cognitively unimpaired amyloid negative; CSF, cerebrospinal fluid; LOESS, locally estimated scatterplot smoothing; mPAC, modified preclinical Alzheimer's cognitive composite; PET, positron emission tomography; ROI, region of interest.

Fig 5: CSF stages for predicting clinical progression

Higher CSF stages groups (4-5) show higher HR of clinical progression compared to lower positive stages (reference: 1-3). Progression from CU or MCI at baseline to AD dementia is shown in A-B. Progression from MCI at baseline to AD dementia is shown in C-D. Progression from CU at baseline to MCI is shown in E-F. Kaplan-Meier curves, as well as the number of participants per group and timepoint are shown in A, C and E, respectively. Cox-proportional hazards models were used to calculate HR[95%CI] of higher CSF stages (4-5) compared to the reference (1-3, B, D and F). These analyses were adjusted for age, sex in all cases, and additionally for clinical status at baseline (CU or MCI) if appropriate.

Abbreviations: AD, Alzheimer's disease; CI, confidence interval; CSF, cerebrospinal fluid; HR, hazard ratios; MCI, mild cognitive impairment.

Fig 6: Replication of main analyses in Knight-ADRC participants

Description of the model is shown in A-B. Cross-validated confusion matrix of the CSF biomarkers of the model is shown in A. Biomarkers are sorted by the time they become abnormal based on the results of SuStaln. Darkness represents the probability of that biomarker of becoming abnormal at that position, with black being 100%. Only amyloid-positive participants are included in this analysis. Description of the CSF levels of the biomarkers included in the model by CSF stage are shown in B for all Knight-ADRC participants. Depiction of individual biomarker levels, not used in the creation of the model, by CSF stage are shown in C. These include biomarkers of amyloid (amyloid-PET) and tau (tau-PET in the meta-temporal ROI) pathologies, neurodegeneration

(cortical thickness in the AD signature areas and CSF NfL) and cognition (global cognitive composite). CSF and AD biomarker levels are z-scored based on a group of CU- participants (n=71) and all increases represent increase in abnormality. Horizontal line is drawn at z-score=1.96 which represents 95%CI of the reference group (CU-). CSF stage 0 represent being classified as normal by the model. Prediction of amyloid-PET (D-G), tau-PET (E-H) and A/T status (by PET, F-I) are shown next. Number of participants in each category are colored in D, E and F. Numbers of participants in each category per CSF stage are shown within the barplots. In G and H, ROC curves were used to determine the CSF stage to optimally classify participants into positive/negative in each case. AUCs, sensitivity and specificity measures from these analyses are shown in the plot. The optimal cut-off in each case is shown as a vertical dashed line in D and E, respectively. Ordinal logistic regression was used for assessing A/T status (I). The heatmap represent the predicted percentage of participants in each A/T group per CSF stage. The most probable (highest percentage) group per CSF stage is framed in black. Amyloid-PET was considered positive if Centiloids>20, tau-PET was considered positive if SUVR at meta-temporal ROI was higher than 1.32. An A-T+ participant (n=1) was excluded from the A/T status analysis. Higher CSF stages groups (4-5) show higher HR of clinical progression compared to lower stages (reference: 1-3, J-M). Progression from CDR=0 or CDR=0.5 at baseline to CDR≥1 is shown in J-K. Progression from CDR=0 at baseline to CDR≥0.5 is shown in L-M. Kaplan-Meier curves, as well as the number of participants per group and timepoint are shown in J and L. Cox-proportional hazards models were used to calculate HR[95%CI] of higher CSF stages (4-5) compared to the reference (1-3, K and M). These analyses were adjusted for age, sex in all cases, and additionally for clinical status at baseline (CDR=0 or CDR=1) if appropriate.

Abbreviations: Aβ, amyloid-β; AD, Alzheimer's disease; AUC, area under the curve; CDR, clinical dementia rating; CI, confidence interval; CU-, cognitively unimpaired amyloid negative; CSF, cerebrospinal fluid; HR, hazard ratio; LOESS, locally estimated scatterplot smoothing; MMSE, Mini-mental state examination; MTBR, microtubule binding region; NfL, neurofilament light; PET, positron emission tomography; ROC, receiver operating characteristic; SuStaln, subtype and stage inference; SUVR, standardized uptake value ratio.

1144

1145 **Extended data**

1146 **Ext Data Fig 1: Creation and optimization of the model**

1147 Initial model with all CSF biomarkers (Aβ42/40, pT217/T217, pT231/T231, pT181/T181,
1148 pT205/T205, MTBR-tau243 and total-tau) is shown in A. First two columns represent

the statistics, CVIC and log-likelihood, of this model for one, two and three subtypes. Each dot in log-likelihood plot represents one of the ten cross-validation sets of data. Lower CVIC and higher log-likelihood values represent better performance of the model. Although higher number of subtypes had higher CVIC, the comparable log-likelihood across subtypes suggests that one subtype is complex enough to explain the variability observed in the data. Cross-validated confusion matrix of the one subtype model is shown in the last column. Here, biomarkers are sorted by the time they become abnormal based on the results of SuStaln. Darkness represents the probability of that biomarker of becoming abnormal at that position, with black being 100%. Given that some biomarkers (pT217/T217, pT231/T231 and pT181/T181) show high overlap on the ordering, we optimized the model by removing these biomarkers systematically (B). All models without one or two of these biomarkers were tested (models 2 to 7). CVIC (left) and cross-validated confusion matrixes (right) for each of these models are shown in B, respectively. CVIC shows that the optimal model was that excluding both pT231/T231 and pT181/T181 (model 7, shown in C). Both CVIC and log-likelihood measures show that one subtype was the optimal model when using this set of biomarkers.

Abbreviations: A β , amyloid- β ; CVIC, cross-validation information criterion; MTBR, microtubule binding region; pT, phosphorylated tau; SuStaln, subtype and stage inference.

Ext Data Fig 2: Demographic, genetic and clinical characteristics by CSF stage

Depiction of basic characteristics of BioFINDER-2 (A-E) and Knight-ADRC (F-J) by CSF stage. Kruskal-Wallis or chi-square tests were used to investigate the association between each of these characteristics and CSF stages. P-values of these tests are shown at the top right of each subplot. Number of individuals in each category are shown inside the barplots.

Abbreviations: AD, Alzheimer's disease; ADD+, Alzheimer's disease dementia amyloid positive; CU-, cognitively unimpaired amyloid negative; CU+, cognitively unimpaired amyloid positive; CSF, cerebrospinal fluid; MCI+, mild cognitive impairment amyloid positive; nonAD, non-Alzheimer's related disease; other Dem, non-Alzheimer's type dementia.

Ext Data Fig 3: Model stability

1185 Depiction of the evolution of CSF stages in BioFINDER-2 (n=220, A-B) and Knight-
1186 ADRC participants (n=51, C-D) with longitudinal CSF available. As longitudinal CSF
1187 A β 42/40 levels were not available for any BioFINDER-2 participant, we imputed this
1188 data with their baseline levels. We show the number of progressors, regressors and
1189 stable participants in A and C, for each cohort respectively. In B and D, we further
1190 show the CSF stages at follow-up. For those Knight-ADRC with more than one
1191 longitudinal visit we took the one more distant from the baseline.
1192 Abbreviations: A β , amyloid- β ; CSF, cerebrospinal fluid.

1193

1194

1195 **Ext Data Fig 4: Tau-PET binding in different Braak regions by CSF stages**

1196 Depiction of tau-PET binding in different areas of tau deposition, by CSF stage in all
1197 BioFINDER-2 (A) and Knight-ADRC participants (B). These areas include regions of
1198 early (Braak I-II), intermediate (Braak II-IV) and late (Braak V-VI) tau deposition. Tau-
1199 PET levels are z-scored based on a group of CU- participants (BioFINDER-2: n=63
1200 and Knight-ADRC: n=71) and all increases represent increase in abnormality.
1201 Significant differences in contiguous CSF stages are shown with asterisks. Horizontal
1202 line is drawn at z-score=1.96 which represents 95%CI of the reference group (CU-).
1203 Smoothed LOESS lines of all AD biomarkers are shown in B for comparison. CSF
1204 stage 0 represent being classified as normal by the model. *: p<0.05; **: p<0.01; ***:
1205 p<0.001.

1206 Abbreviations: A β , amyloid- β ; AD, Alzheimer's disease; CI, confidence interval; CU-,
1207 cognitively unimpaired amyloid negative; CSF, cerebrospinal fluid; LOESS, locally
1208 estimated scatterplot smoothing; PET, positron emission tomography; ROI, region of
1209 interest.

1210

1211

1212 **Ext Data Fig 5: Cognitive composites by CSF stages**

1213 Depiction of different cognitive measures, by CSF stage in BioFINDER-2 (A) and
1214 Knight-ADRC participants (B). These measures include: mPACC (ADAS-delayed,
1215 animal fluency, MMSE and TMT-A), memory (ADAS-delayed and ADAS-immediate),
1216 executive function (TMT-A, TMT-B and symbols digit), language (animal fluency and
1217 BNT-15) and visuospatial (VOSP-cube and VOSP-incomplete) for BioFINDER-2. For
1218 Knight-ADRC we had a global cognitive composite (FCSRT, animals, TMT-A and TMT-
1219 B), an executive function composite (TMT-A and TMT-B), a memory (FCSRT) and
1220 language (animal fluency) tests. Cognitive scores are z-scored based on a group of
1221 CU- participants (BioFINDER-2: n=60 and Knight-ADRC: n=71) and all increases

represent increase in abnormality. Significant differences in contiguous CSF stages are shown with asterisks. Horizontal line is drawn at z-score=1.96 which represents 95%CI of the reference group (CU-). Smoothed LOESS lines of all AD biomarkers are shown in B for comparison. We excluded non-AD dementia patients to avoid bias in these analyses. CSF stage 0 represents being classified as normal by the model. *: $p<0.05$; **: $p<0.01$; ***: $p<0.001$.

Abbreviations: AD, Alzheimer's disease; ADAS, Alzheimer's disease assessment scale; BNT, Boston naming test; CI, confidence interval; CU-, cognitively unimpaired amyloid negative; CSF, cerebrospinal fluid; FCSRT, free and cued selective reminding test; LOESS, locally estimated scatterplot smoothing; MMSE, Mini-Mental state examination; mPACC, modified version of preclinical Alzheimer's disease cognitive composite; TMT, trial making test; VOSP, visual object and space perception battery.

Ext Data Fig 6: Individual CSF stages for predicting clinical progression

Kaplan-Meier curves for all individual CSF stages in BioFINDER-2 (A-C) and Knight-ADRC (D-E) participants. For BioFINDER-2, progression from CU or MCI at baseline to AD dementia is shown in A; progression from MCI at baseline to AD dementia is shown in B and; progression from CU at baseline to MCI is shown in C. For Knight-ADRC, progression from CDR=0 or CDR=0.5 at baseline to $CDR\geq 1$ is shown in D and; progression from CDR=0 at baseline to $CDR\geq 0.5$ is shown in E.

Abbreviations: AD, Alzheimer's disease; CDR, clinical dementia rating; CSF, cerebrospinal fluid; CU, cognitively unimpaired; MCI, mild cognitive impairment.

Ext Data Fig 7: Individual biomarker levels by CSF stage in Knight-ADRC participants


Individual CSF biomarker levels, included in the model, by CSF stage participants are shown in A including all Knight-ADRC participants. Depiction of individual AD-biomarker levels, not used in the creation of the model, per CSF stage are shown in B. All biomarker levels are z-scored based on a group of CU- participants ($n=71$) and all increases represent increase in abnormality. Significant differences in contiguous CSF stages are shown with asterisks. Horizontal line is drawn at z-score=1.96 which represents 95%CI of the reference group (CU-). CSF stage 0 represent being classified as normal by the model. Black dots and vertical lines represent mean and SD per CSF stage. *: $p<0.05$; **: $p<0.01$; ***: $p<0.001$.

Abbreviations: A β , amyloid- β ; CI, confidence interval; CU-, cognitively unimpaired amyloid negative; CSF, cerebrospinal fluid; MMSE, Mini-Mental state examination; MTBR, microtubule binding region; NfL, neurofilament light; PET, positron emission tomography; pT, phosphorylated tau; SuStaln, subtype and stage inference.


Ext Data Fig 8: Excluded CSF biomarkers by CSF stage

Depiction of the CSF biomarkers excluded in the optimal model (pT231/T231 and pT181/T181) by CSF stage in BioFINDER-2 (A-B) and Knight-ADRC (C-D) participants. CSF pT217/T217 is also shown for comparison. CSF levels are z-scored based on a group of CU- participants (BioFINDER-2: n=63, Knight-ADRC: n=71) and all increases represent increase in abnormality. Significant differences in contiguous CSF stages are shown with asterisks. Horizontal line is drawn at z-score=1.96 which represents 95%CI of the reference group (CU-). Smoothed LOESS lines of all CSF biomarkers are shown in B (BioFINDER-2) and D (Knight-ADRC) for comparison. CSF stage 0 represent being classified as normal by the model. Black dots and vertical lines represent mean and SD per CSF stage, respectively. *: p<0.05; **: p<0.01; ***: p<0.001.


Abbreviations: A β , amyloid- β ; CI, confidence interval; CU-, cognitively unimpaired amyloid negative; CSF, cerebrospinal fluid; LOESS, locally estimated scatterplot smoothing; MTBR, microtubule binding region; pT, phosphorylated tau; SuStaln, subtype and stage inference.









A




B






A**B**


A Progression from CU/MCI to AD dementia




C Progression from MCI to AD dementia




E Progression from CU to MCI




B




D




F




A




B




C




D




E




F




G




H




I




J Progression from CDR ≤ 0.5 to CDR ≥ 1




L Progression from CDR = 0 to CDR ≥ 0.5




K




M




A Initial model




B Optimization




C Final model




A Age




B Years of education




C Sex



D APOE-ε4 carriership




E Diagnosis




Knight-ADRC


F Age




G Years of education




H Sex



I APOE-ε4 carriership




J Diagnosis



BioFINDER-2




Knight-ADRC




BioFINDER-2

medRxiv preprint doi: <https://doi.org/10.1101/2023.07.14.23292650>; this version posted July 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

A






B




Knight-ADRC

C




D




A

medRxiv preprint doi: <https://doi.org/10.1101/2023.07.14.23292650>; this version posted July 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.




B




Knight-ADRC

C




D




BioFINDER-2


A Progression from CU/MCI to AD dementia



B Progression from MCI to AD dementia




C Progression from CU to MCI







Knight-ADRC

D Progression from CDR ≤ 0.5 to CDR ≥ 1






E Progression from CDR = 0 to CDR ≥ 0.5




A**B**

medRxiv preprint doi: <https://doi.org/10.1101/2023.07.14.23292650>; this version posted July 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

A






B



Knight-ADRC

C



D

